Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$98.98 - $115.74 $83.9 Million - $98.2 Million
848,150 Added 62.15%
2,212,745 $256 Million
Q2 2023

Aug 14, 2023

BUY
$96.34 - $112.38 $48.4 Million - $56.4 Million
502,189 Added 58.23%
1,364,595 $140 Million
Q1 2023

May 15, 2023

SELL
$107.32 - $113.5 $79.6 Million - $84.2 Million
-741,412 Reduced 46.23%
862,406 $94.1 Million
Q4 2022

Feb 14, 2023

BUY
$62.39 - $113.8 $27.5 Million - $50.1 Million
440,287 Added 37.84%
1,603,818 $183 Million
Q3 2022

Nov 14, 2022

BUY
$58.92 - $84.67 $68.6 Million - $98.5 Million
1,163,531 New
1,163,531 $72 Million
Q3 2021

Nov 15, 2021

SELL
$91.91 - $110.37 $33.7 Million - $40.4 Million
-366,372 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$86.24 - $95.92 $25.9 Million - $28.8 Million
299,979 Added 451.82%
366,372 $34.3 Million
Q1 2021

May 17, 2021

BUY
$71.83 - $95.48 $4.77 Million - $6.34 Million
66,393 New
66,393 $6.11 Million
Q4 2020

Feb 16, 2021

SELL
$67.0 - $84.39 $12 Million - $15.1 Million
-178,635 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$55.23 - $79.93 $6.8 Million - $9.83 Million
123,042 Added 221.33%
178,635 $13.9 Million
Q2 2020

Aug 14, 2020

SELL
$30.2 - $56.98 $12.4 Million - $23.5 Million
-411,656 Reduced 88.1%
55,593 $3.09 Million
Q1 2020

May 15, 2020

SELL
$24.87 - $38.56 $12.1 Million - $18.8 Million
-488,028 Reduced 51.09%
467,249 $13.8 Million
Q4 2019

Feb 14, 2020

BUY
$25.43 - $36.67 $17.2 Million - $24.8 Million
675,840 Added 241.86%
955,277 $34.6 Million
Q3 2019

Nov 14, 2019

SELL
$23.0 - $27.97 $13.1 Million - $16 Million
-570,560 Reduced 67.12%
279,437 $7.61 Million
Q2 2019

Aug 14, 2019

BUY
$22.81 - $28.48 $19.4 Million - $24.2 Million
849,997 New
849,997 $20.5 Million

Others Institutions Holding HZNP

About Horizon Therapeutics Public Ltd Co


  • Ticker HZNP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 230,384,000
  • Description
  • Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...
More about HZNP
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.